Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Ghatalia · SciRah

Researcher profile · Semantic Scholar

P. Ghatalia

Share profile

P. Ghatalia — researcher profile on SciRah

h-index: 27
Works: 146
Citations: 2,615

Most-cited papers

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
T. Choueiri, T. Powles, K. Peltola, G. de Velasco +29 more
2024New England Journal of Medicine163 citations
Semantic Scholar
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
J. Conroy, S. Pabla, M. Nesline, S. Glenn +36 more
2019Journal of Immunotherapy for Cancer85 citations Open access
Semantic Scholar
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
S. Pabla, J. Conroy, M. Nesline, S. Glenn +42 more
2019Journal of Immunotherapy for Cancer83 citations Open access
Semantic Scholar
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
B. Cotta, T. Choueiri, M. Cieslik, P. Ghatalia +8 more
2023European Urology74 citations Open access
Semantic Scholar
LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
L. Albiges, B. Rini, K. Peltola, G. A. De Velasco Oria +16 more
2023Annals of Oncology54 citations
Semantic Scholar
20 years of Histone Lysine Demethylases: From Discovery to the Clinic and Beyond
Zach H. Gray, Madison A. Honer, P. Ghatalia, Yang Shi +1 more
2025Cell52 citations Open access
Semantic Scholar
A phase 2 trial of risk enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +15 more
2024Journal of Clinical Oncology42 citations Open access
Semantic Scholar
A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +16 more
202134 citations
Semantic Scholar
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +16 more
2023Journal of Clinical Oncology31 citations Open access
Semantic Scholar
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
P. Ghatalia, E. Ross, M. Zibelman, F. Anari +16 more
2025Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
K. Zarrabi, E. Handorf, B. Miron, M. Zibelman +4 more
2022The Oncologist27 citations Open access
Semantic Scholar
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
H. Jang, G. Hostetter, A. MacFarlane, Zachary B. Madaj +23 more
2023Clinical Cancer Research26 citations Open access
Semantic Scholar
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real World Multi-institutional Analysis
P. Ghatalia, E. Handorf, D. Geynisman, Meng-Ying Deng +9 more
2022Journal of Urology24 citations Open access
Semantic Scholar
PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression
Hyeyoung Nam, A. Kundu, Garrett J. Brinkley, D. Chandrashekar +10 more
2020Matrix Biology23 citations Open access
Semantic Scholar
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Marijo Bilusic, N. Toney, R. Donahue, S. Wróblewski +10 more
2022Prostate Cancer and Prostatic Diseases21 citations Open access
Semantic Scholar
Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.
G. Hemenway, Jonathan F. Anker, P. Riviere, B. Rose +2 more
2024American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting18 citations Open access
Semantic Scholar
Role of immunotherapy in localized muscle invasive urothelial cancer
J. Kaur, Woonyoung Choi, D. Geynisman, E. Plimack +1 more
2021Therapeutic Advances in Medical Oncology17 citations Open access
Semantic Scholar
Systemic therapy in bladder preservation.
D. Girardi, P. Ghatalia, Parminder Singh, G. Iyer +2 more
2020Urologic oncology15 citations Open access
Semantic Scholar
Randomized phase 2 dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
N. Agarwal, J. Brugarolas, P. Ghatalia, S. George +15 more
2024Annals of Oncology14 citations Open access
Semantic Scholar
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
P. Ghatalia, E. Plimack
2020The Journal of the National Comprehensive Cancer Network14 citations Open access
Semantic Scholar
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
Tian Zhang, S. Pabla, Felicia L. Lenzo, J. Conroy +28 more
2020Oncoimmunology14 citations Open access
Semantic Scholar
Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic
P. Ghatalia, Chad H. Smith, Arthur Winer, J. Gou +10 more
2019Frontiers in Oncology13 citations Open access
Semantic Scholar
Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care
Jerry H. Fu, C. Fu, Robert S. Wang, D. Geynisman +5 more
2023Current Oncology Reports12 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.
P. Ghatalia, E. Ross, M. Zibelman, F. Anari +16 more
2026Journal of Clinical Oncology11 citations Open access
Semantic Scholar
39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials
T. Choueiri, P. Ghatalia, G. de Velasco, L. Albiges +23 more
2024The Oncologist11 citations Open access
Semantic Scholar
LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
B. Rini, C. Rodriguez, L. Albiges, K. Jalkanen +16 more
2024Annals of Oncology11 citations
Semantic Scholar
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
T. Powles, T. Choueiri, L. Albiges, K. Peltola +22 more
2025The Lancet Oncology10 citations
Semantic Scholar
Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer
P. Ghatalia, E. Plimack
2019Nature Medicine9 citations
Semantic Scholar
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort Evaluation
L. Bukavina, Rashida Ginwala, M. Eltoukhi, M. Sindhani +16 more
2024Cancer Research Communications8 citations Open access
Semantic Scholar
1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study
N. Agarwal, J. Brugarolas, P. Ghatalia, S. George +15 more
2023Annals of Oncology8 citations Open access
Semantic Scholar
Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
P. Ghatalia, J. Gordetsky, F. Kuo, E. Dulaimi +9 more
2019Journal of Immunotherapy for Cancer8 citations Open access
Semantic Scholar
Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
T. Powles, L. Albiges, K. Jalkanen, G. de Velasco +16 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
Neoadjuvant chemotherapy with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in patients with muscle invasive bladder cancer: A retrospective age-stratified analysis on safety and efficacy
G. Hemenway, Bianca Lewis, P. Ghatalia, F. Anari +6 more
2022European Urology Oncology6 citations
Semantic Scholar
Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates
Uttam Satyal, Henkel Valentine, David Liu, M. Slifker +25 more
2024JCO Precision Oncology5 citations
Semantic Scholar
Role of perioperative immunotherapy in localized renal cell carcinoma
J. Kaur, G. Patil, D. Geynisman, P. Ghatalia
2023Therapeutic Advances in Medical Oncology5 citations Open access
Semantic Scholar
Muscle invasive bladder cancer: where is the field headed?
P. Ghatalia, J. Kaur, G. Sonpavde
2023Expert Opinion on Biological Therapy5 citations
Semantic Scholar
Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles.
Anumita Chakraborty, J. Hasler, E. Handorf, F. Anari +5 more
2024Clinical Genitourinary Cancer4 citations
Semantic Scholar
Influence of First-line Chemotherapy Regimen on Survival Outcomes of Patients with Advanced Urothelial Carcinoma who Received Second-line Immune Checkpoint Inhibitors
B. Miron, E. Handorf, K. Zarrabi, M. Zibelman +4 more
2022Urologic oncology4 citations Open access
Semantic Scholar
First-line Immunotherapy in Metastatic Urothelial Carcinoma.
P. Ghatalia, M. Zibelman, D. Geynisman, E. Plimack
2020European Urology Focus4 citations
Semantic Scholar
Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.
M. Atkins, P. Ghatalia, Jaime Merchan, S. George +15 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma
P. Ghatalia, E. Plimack
2023Nature Reviews Clinical Oncology3 citations
Semantic Scholar
Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma
P. Ghatalia, Aangi J. Shah, M. Slifker
2022Kidney Cancer3 citations Open access
Semantic Scholar
Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
E. Demidova, P. Ghatalia, S. Arora
2021European Urology3 citations
Semantic Scholar
Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.
D. Kilari, A. Szabo, P. Ghatalia, T. Rose +16 more
20213 citations
Semantic Scholar
Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.
K. Zarrabi, E. Handorf, B. Miron, M. Zibelman +4 more
2021Journal of Clinical Oncology3 citations
Semantic Scholar
Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
P. Ghatalia, E. Handorf, M. Deng, M. Zibelman +9 more
20213 citations
Semantic Scholar
Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).
N. Agarwal, J. Brugarolas, P. Ghatalia, S. George +16 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
A Practical Guide for the Management of Toxicities Associated with Belzutifan.
Joy Li, P. Ghatalia
2025European Urology Focus2 citations
Semantic Scholar
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.
A. Armstrong, N. Clarke, M. Oya, G. Procopio +14 more
2023European Urology Oncology2 citations Open access
Semantic Scholar
A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
M. Zibelman, M. Carducci, Y. Ged, A. Molina +14 more
2022Journal of Clinical Oncology2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Geynisman×21
Invite
D. Geynisman — researcher profile on SciRah
M. Zibelman×20
Invite
M. Zibelman — researcher profile on SciRah
E. Plimack×18
Invite
E. Plimack — researcher profile on SciRah
F. Anari×14
Invite
F. Anari — researcher profile on SciRah

×8

Invite

P. Abbosh — researcher profile on SciRah

Invite

R. Viterbo — researcher profile on SciRah

Invite

M. Smaldone — researcher profile on SciRah

Invite

T. Powles — researcher profile on SciRah

Invite

M. Burotto — researcher profile on SciRah

Invite

D. Vickery — researcher profile on SciRah

Invite

A. Kutikov — researcher profile on SciRah

Invite

R. Perini — researcher profile on SciRah